MaxCyte Inc (NASDAQ: MXCT) open the trading on Thursday, with a bit cautious approach as it glided -6.12% to $3.07, before settling in for the price of $3.27 at the close. Taking a more long-term approach, MXCT posted a 52-week range of $2.76-$5.26.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that the giant of the Healthcare sector posted annual sales growth of 13.60% over the last 5 years. Meanwhile, its Annual Earning per share during the time was -11.37%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 12.82%. This publicly-traded company’s shares outstanding now amounts to $105.71 million, simultaneously with a float of $97.85 million. The organization now has a market capitalization sitting at $325.51 million. At the time of writing, stock’s 50-day Moving Average stood at $4.07, while the 200-day Moving Average is $4.07.
MaxCyte Inc (MXCT) Ownership Facts and Figures
Sometimes it helps to make our mind if we keep our tabs on how bigger investors are working with the stock of the Medical Devices industry. MaxCyte Inc’s current insider ownership accounts for 7.71%, in contrast to 71.04% institutional ownership. According to the most recent insider trade that took place on Mar 18 ’25, this organization’s Chief Commercial Officer sold 1,211 shares at the rate of 3.18, making the entire transaction reach 3,850 in total value, affecting insider ownership by 59,439. Preceding that transaction, on Mar 18 ’25, Company’s GENERAL COUNSEL sold 353 for 3.18, making the whole transaction’s value amount to 1,122. This particular insider is now the holder of 64,219 in total.
MaxCyte Inc (MXCT) Earnings and Revenue Records
MaxCyte Inc’s EPS increase for this current 12-month fiscal period is 12.82% and is forecasted to reach -0.30 in the upcoming year.
MaxCyte Inc (NASDAQ: MXCT) Trading Performance Indicators
Let’s observe the current performance indicators for MaxCyte Inc (MXCT). It’s Quick Ratio in the last reported quarter now stands at 10.32. The Stock has managed to achieve an average true range (ATR) of 0.23. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 8.43.
In the same vein, MXCT’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -0.39, a figure that is expected to reach -0.10 in the next quarter, and analysts are predicting that it will be -0.30 at the market close of one year from today.
Technical Analysis of MaxCyte Inc (MXCT)
[MaxCyte Inc, MXCT] recent stats showed that its last 5-days Average volume was superior the volume it posted in the year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 52.27% While, its Average True Range was 0.23.
Raw Stochastic average of MaxCyte Inc (MXCT) in the period of the previous 100 days is set at 12.70%, which indicates a major fall in contrast to 37.80% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 61.96% that was higher than 59.86% volatility it exhibited in the past 100-days period.
